Yining Feng
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Yining Feng has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
- Tianzhu Guan
School of Food Science and Engineering, Yangzhou University, Yangzhou, China
4 shared publications - Jie Zhang
College of Food Science and Engineering, Jilin University, Changchun, China
2 shared publications - Ayyoob Ujala
School of Food Science and Engineering, Yangzhou University, Yangzhou 225127, China
1 shared publication - Bo Wang
College of Food Science and Engineering, Yangzhou University, Yangzhou 225009, China
1 shared publication - Cai You
Health Science Center, Ningbo University, Ningbo 315211, China
1 shared publication - Chengjun Wu
School of Food Science and Engineering, Yangzhou University, Yangzhou 225127, China
1 shared publication
Latest Publications
- Open Access
Decoding the Multi-Component Synergy of Fu Ling Yin Zi for Anti-Oxidative Stress Applications: Formulation Optimization, Molecular Docking, Cell-Based Validation, and 3D-Printed Dysphagia-Friendly Diets
Developing functional foods that address both oxidative stress and physiological challenges like dysphagia is a critical frontier in personalized nutrition. This study investigates the multi-component synergy of Fu Ling Yin Zi (FLYZ), a traditional dietary therapy, and translates its functional properties into a 3D-printed dysphagia-friendly food. Using response surface methodology, the optimal FLYZ formulation was established at a 5:1:5 ratio of Poria cocos (Schw.) Wolf., Amygdalus communis Vas, and Citrus reticulata. Network pharmacology and molecular docking suggested that FLYZ’s active compounds (e.g., nobiletin, stigmasterol, tangeretin, l-SPD, glabridin, estrone) may mitigate oxidative stress via multiple targets (PTGS2, AKT1, TNF, ESR1, MMP9, and MAOA), with pathway analysis pointing to a potential role of the AKT1/GSK3β/HIF-1α axis. Subsequent in vitro cellular assays demonstrated that FLYZ enhanced antioxidant enzyme activities, reduced intracellular ROS, and modulated the expression of associated genes, supporting a potential link to this pathway. To actualize these functional benefits for patients with swallowing difficulties, a novel 3D-printing ink incorporating FLYZ and walnut oil within a hydrogel matrix (3% xanthan gum, 3% pectin, 1.5% carrageenan) was developed. The printed constructs exhibited excellent shape fidelity and, based on standardized IDDSI fork and spoon tests, were categorized as level 4 (pureed/extremely thick). Furthermore, a simulated in vitro digestion model showed that the colloidal network significantly protected FLYZ’s polyphenols and flavonoids, markedly improving their bioaccessibility and post-digestion antioxidant capacity. Collectively, this work establishes an integrated approach that combines predictive molecular profiling with advanced 3D food printing, thereby supporting the development of future foods tailored for personalized nutrition.
Open AccessDecoding the Multi-Component Synergy of Fu Ling Yin Zi for Anti-Oxidative Stress Applications: Formulation Optimization, Molecular Docking, Cell-Based Validation, and 3D-Printed Dysphagia-Friendly Diets
Developing functional foods that address both oxidative stress and physiological challenges like dysphagia is a critical frontier in personalized nutrition. This study investigates the multi-component synergy of Fu Ling Yin Zi (FLYZ), a traditional dietary therapy, and translates its functional properties into a 3D-printed dysphagia-friendly food. Using response surface methodology, the optimal FLYZ formulation was established at a 5:1:5 ratio of Poria cocos (Schw.) Wolf., Amygdalus communis Vas, and Citrus reticulata. Network pharmacology and molecular docking suggested that FLYZ’s active compounds (e.g., nobiletin, stigmasterol, tangeretin, l-SPD, glabridin, estrone) may mitigate oxidative stress via multiple targets (PTGS2, AKT1, TNF, ESR1, MMP9, and MAOA), with pathway analysis pointing to a potential role of the AKT1/GSK3β/HIF-1α axis. Subsequent in vitro cellular assays demonstrated that FLYZ enhanced antioxidant enzyme activities, reduced intracellular ROS, and modulated the expression of associated genes, supporting a potential link to this pathway. To actualize these functional benefits for patients with swallowing difficulties, a novel 3D-printing ink incorporating FLYZ and walnut oil within a hydrogel matrix (3% xanthan gum, 3% pectin, 1.5% carrageenan) was developed. The printed constructs exhibited excellent shape fidelity and, based on standardized IDDSI fork and spoon tests, were categorized as level 4 (pureed/extremely thick). Furthermore, a simulated in vitro digestion model showed that the colloidal network significantly protected FLYZ’s polyphenols and flavonoids, markedly improving their bioaccessibility and post-digestion antioxidant capacity. Collectively, this work establishes an integrated approach that combines predictive molecular profiling with advanced 3D food printing, thereby supporting the development of future foods tailored for personalized nutrition.
- Open Access
Recent Advances on Sensor Technologies for the Monitoring of Tumor Markers
Sensor technologies have been increasingly recognized as a cornerstone for advancing tumor diagnostics amid the global health challenge posed by cancer. Traditional diagnostic methods are often constrained by inherent tumor heterogeneity, while liquid biopsy has emerged as a transformative minimally invasive alternative, with biosensors playing a pivotal role in its clinical translation. This review summarizes the progress of tumor diagnostic biosensors, focusing on electrochemical and fluorescent sensors. Electrochemical sensors excel in quantitative precision, miniaturization, and point-of-care (POCT) applicability, enabling ultra-sensitive detection of biomarkers such as circulating tumor cells, circulating tumor DNA, and exosomes through nanomaterial modification and signal amplification strategies. Fluorescent sensors, meanwhile, offer superior multiplexing capability and in situ imaging performance, which are further enhanced by novel nanomaterials. Additionally, it covers other promising sensor types including Surface-Enhanced Raman Scattering, microfluidic, photoelectrochemical, field-effect transistor, and clustered regularly interspaced short palindromic repeats and CRISPR-associated proteins-based sensors. Current research efforts are concentrated on multiplexed detection, point-of-care integration, and translation toward higher-order clinical functions such as cancer subtype discrimination, risk stratification, and prognosis. Future directions will focus on multimodal integration, intelligent data analysis, and prospective clinical validation against hard endpoints to facilitate the implementation of precision oncology.
Open AccessRecent Advances on Sensor Technologies for the Monitoring of Tumor Markers
Sensor technologies have been increasingly recognized as a cornerstone for advancing tumor diagnostics amid the global health challenge posed by cancer. Traditional diagnostic methods are often constrained by inherent tumor heterogeneity, while liquid biopsy has emerged as a transformative minimally invasive alternative, with biosensors playing a pivotal role in its clinical translation. This review summarizes the progress of tumor diagnostic biosensors, focusing on electrochemical and fluorescent sensors. Electrochemical sensors excel in quantitative precision, miniaturization, and point-of-care (POCT) applicability, enabling ultra-sensitive detection of biomarkers such as circulating tumor cells, circulating tumor DNA, and exosomes through nanomaterial modification and signal amplification strategies. Fluorescent sensors, meanwhile, offer superior multiplexing capability and in situ imaging performance, which are further enhanced by novel nanomaterials. Additionally, it covers other promising sensor types including Surface-Enhanced Raman Scattering, microfluidic, photoelectrochemical, field-effect transistor, and clustered regularly interspaced short palindromic repeats and CRISPR-associated proteins-based sensors. Current research efforts are concentrated on multiplexed detection, point-of-care integration, and translation toward higher-order clinical functions such as cancer subtype discrimination, risk stratification, and prognosis. Future directions will focus on multimodal integration, intelligent data analysis, and prospective clinical validation against hard endpoints to facilitate the implementation of precision oncology.
- Open Access
Recent Progress in Health Benefits of Hederagenin and Its Glycosides
Hederagenin, a pentacyclic triterpenoid saponin from various medicinal plants, shows immense therapeutic potential; however, its inherent low bioavailability severely hinders its clinical translation. This comprehensive review synthesizes recent studies on the health benefits of hederagenin and its glycosides, critically the chemical modification strategies and pharmacological mechanisms aimed at optimizing its bioactivity. Key findings reveal that its broad anticancer and anti-inflammatory activities largely stem from its capacity to modulate crucial cellular signaling pathways, including the NF-κB, PI3K/Akt, and MAPK. Structural modification, particularly intelligent derivatization at the C-28 position, is a central strategy to overcome its pharmacokinetic deficiencies and significantly boost cytotoxicity. Furthermore, its unique pro-oxidant function within cancer cells, achieved by inhibiting the Nrf2-ARE antioxidant pathway, offers a novel approach for selective chemotherapeutics. For the clinical translation of hederagenin, we propose a strategic focus on derivatization through multi-target hybrids and sophisticated delivery systems. This approach is essential for addressing its pharmacokinetic barriers while strategically leveraging its context-dependent pro-oxidant effects.
Open AccessRecent Progress in Health Benefits of Hederagenin and Its Glycosides
Hederagenin, a pentacyclic triterpenoid saponin from various medicinal plants, shows immense therapeutic potential; however, its inherent low bioavailability severely hinders its clinical translation. This comprehensive review synthesizes recent studies on the health benefits of hederagenin and its glycosides, critically the chemical modification strategies and pharmacological mechanisms aimed at optimizing its bioactivity. Key findings reveal that its broad anticancer and anti-inflammatory activities largely stem from its capacity to modulate crucial cellular signaling pathways, including the NF-κB, PI3K/Akt, and MAPK. Structural modification, particularly intelligent derivatization at the C-28 position, is a central strategy to overcome its pharmacokinetic deficiencies and significantly boost cytotoxicity. Furthermore, its unique pro-oxidant function within cancer cells, achieved by inhibiting the Nrf2-ARE antioxidant pathway, offers a novel approach for selective chemotherapeutics. For the clinical translation of hederagenin, we propose a strategic focus on derivatization through multi-target hybrids and sophisticated delivery systems. This approach is essential for addressing its pharmacokinetic barriers while strategically leveraging its context-dependent pro-oxidant effects.
- Open Access
Patrinia scabiosaefolia L. Modulates the Intestinal Microecology to Treat DSS-Induced Ulcerative Colitis: UHPLC-OE-MS/MS, Network Pharmacology, and Experimental Validation
Patrinia scabiosaefolia L. (P. scabiosaefolia), a traditional food and medicinal plant, is used to treat internal inflammation. This study investigated the mechanisms by which P. scabiosaefolia improves ulcerative colitis (UC) via combined UHPLC-OE-MS/MS, network pharmacology, molecular docking, and animal experiments. A total of 72 compounds were detected in the P. scabiosaefolia extraction, with 15 key components (ranking by degree value) selected for further analysis. GO enrichment analysis suggested that PS may alleviate UC-related renal dysfunction by modulating immune responses, inflammation, and cell signaling pathways. Based on protein–protein interaction results, five core targets of P. scabiosaefolia in UC (ranking by degree value) were identified, and molecular docking revealed strong binding free affinity (<−7 kcal/mol) of active components (Vulgarin and 4-(Diphenylphosphino)benzoic acid) with TNF, AKT1, CASP3, BCL2, and MMP9. In animal experiments, P. scabiosaefolia-treated mice showed significant reductions in IL-6, TNF-α, LPS, and D-Lactate levels (p < 0.05); improved colon histopathological damage; and significantly increased the mRNA expression of tight junction proteins (ZO-1, Claudin, OCC) in colon tissue (p < 0.05). Furthermore, P. scabiosaefolia-treated mice exhibited a significant increase in beneficial gut bacteria (Enterococcus and Lactobacillus) (p < 0.05), effectively restoring the gut imbalance caused by DSS. In conclusion, P. scabiosaefolia can treat UC through the modulation of the intestinal microecology.
Open AccessPatrinia scabiosaefolia L. Modulates the Intestinal Microecology to Treat DSS-Induced Ulcerative Colitis: UHPLC-OE-MS/MS, Network Pharmacology, and Experimental Validation
Patrinia scabiosaefolia L. (P. scabiosaefolia), a traditional food and medicinal plant, is used to treat internal inflammation. This study investigated the mechanisms by which P. scabiosaefolia improves ulcerative colitis (UC) via combined UHPLC-OE-MS/MS, network pharmacology, molecular docking, and animal experiments. A total of 72 compounds were detected in the P. scabiosaefolia extraction, with 15 key components (ranking by degree value) selected for further analysis. GO enrichment analysis suggested that PS may alleviate UC-related renal dysfunction by modulating immune responses, inflammation, and cell signaling pathways. Based on protein–protein interaction results, five core targets of P. scabiosaefolia in UC (ranking by degree value) were identified, and molecular docking revealed strong binding free affinity (<−7 kcal/mol) of active components (Vulgarin and 4-(Diphenylphosphino)benzoic acid) with TNF, AKT1, CASP3, BCL2, and MMP9. In animal experiments, P. scabiosaefolia-treated mice showed significant reductions in IL-6, TNF-α, LPS, and D-Lactate levels (p < 0.05); improved colon histopathological damage; and significantly increased the mRNA expression of tight junction proteins (ZO-1, Claudin, OCC) in colon tissue (p < 0.05). Furthermore, P. scabiosaefolia-treated mice exhibited a significant increase in beneficial gut bacteria (Enterococcus and Lactobacillus) (p < 0.05), effectively restoring the gut imbalance caused by DSS. In conclusion, P. scabiosaefolia can treat UC through the modulation of the intestinal microecology.